JOHN KIRKWOOD to Salvage Therapy
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Salvage Therapy.
Connection Strength
0.040
-
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol. 2020 03; 21(3):358-372.
Score: 0.025
-
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013 Feb 10; 31(5):616-22.
Score: 0.015